Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Price
Data
About
ABBV stock price forecast
News
Competitors
Tokenization
Crypto
FAQ
AbbVie Inc. stock logo

AbbVie Inc.

ABBV·NYSE

Last updated as of 2026-02-10 07:02 EST. Stock price information is sourced from TradingView and reflects real-time market prices.

Insights
Calculator
News

ABBV stock price change

On the last trading day, ABBV stock closed at 221.62 USD, with a price change of -0.81% for the day.
Trade stock futures

About Bitget

The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more

ABBV key data

Previous close221.62 USD
Market cap391.68B USD
Volume1.08M
P/E ratio93.62
Dividend yield (TTM)2.98%
Dividend amount1.73 USD
Last ex-dividend dateJan 16, 2026
Last payment dateFeb 17, 2026
EPS diluted (TTM)2.37 USD
Net income (FY)4.24B USD
Revenue (FY)56.33B USD
Next report dateFeb 4, 2026
EPS estimate2.650 USD
Revenue estimate16.41B USD
Shares float1.77B
Beta (1Y)0.27
Tokenized stocks

Have you heard of tokenized stocks?

A new way to trade stocks — anytime, anywhere, 24/7.

Learn more

AbbVie Inc. overview

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinsons, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Sector
Health technology
Industry
Pharmaceuticals: Major
CEO
Robert A. Michael
Headquarters
North Chicago
Website
abbvie.com
Founded
2011
Employees (FY)
55K
Change (1Y)
+5K +10.00%
Revenue / Employee (1Y)
1.02M USD
Net income / Employee (1Y)
77.05K USD

ABBV Pulse

Daily updates on ABBV stock prices, fund flows, and market news, generated by AI and reviewed by our team of analysts. Always DYOR.

• ABBV Stock Price 24h change: +2.01%. From 219.02 USD to 223.43 USD. The rebound was driven by investors reassessing the company's 2026 growth outlook after a temporary dip following its Q4 earnings report, alongside positive momentum from new regulatory filings for its drug Rinvoq.
• From a technical perspective, the stock is showing a "bullish recovery" signal: the price has crossed back above its 8-day and 20-day Simple Moving Averages (SMAs). While the MACD remains slightly bearish (-0.20), the RSI at 52.70 indicates neutral-to-bullish momentum, suggesting the stock is recovering from recent selling pressure without being overbought.
• AbbVie submitted regulatory applications to the FDA and EMA for Rinvoq (upadacitinib) to treat non-segmental vitiligo, aiming to address a major unmet medical need in systemic therapy.
• Despite a recent 4% post-earnings dip, analysts noted that Humira sales beat expectations by nearly 30%, while the company issued an upbeat 2026 revenue guidance of $67 billion.
• AbbVie launched the "Love in Mind" campaign to highlight the emotional impact of migraines on romantic relationships, aiming to increase patient engagement for its migraine portfolio.
• The U.S. health department (HHS) recently dropped a 340B drug rebate pilot program following a court setback, a move closely watched by major pharmaceutical manufacturers for its impact on drug pricing and discounts.
• Eikon Therapeutics launched the largest biotech IPO of 2026 so far, raising $381 million, though its 17% first-day drop reflects continued investor caution regarding early-stage biotech valuations.
See more
about 20h ago
• ABBV Stock Price 24h change: +2.01%. From 219.02 USD to 223.43 USD.
The price rose as investors digested the robust FY 2025 earnings report and upbeat 2026 guidance, recovering from a post-earnings sell-off earlier in the week. Strong growth in immunology (Skyrizi/Rinvoq) and neuroscience helped offset declines in oncology and aesthetics.
• From a technical perspective, the stock is showing a "bullish recovery within a rising trend": ABBV remains in a medium-term rising trend channel. Currently, the stock price (223.43 USD) is above its 8-day SMA (221.62) and 200-day SMA (209.64), providing a buy signal, though it faces immediate resistance near 225-236 USD.
• AbbVie reported Q4 2025 revenue of $16.6 billion, driven by over 30% growth in Skyrizi and Rinvoq, effectively managing the "Humira patent cliff" impact.
• AbbVie submitted regulatory applications to the FDA and EMA for Rinvoq (upadacitinib) on February 3, seeking a new indication for treating adult and adolescent patients with vitiligo.
• Morningstar maintained a wide-moat rating for AbbVie on February 5, focusing on upcoming Phase 2 data for novel combination therapies involving Skyrizi for Crohn’s disease.
• The pharmaceutical sector is pivoting toward AI-driven R&D in 2026, with major firms like GSK launching multi-million dollar partnerships to use virtual cell models for drug discovery.
• Global health policy uncertainty persists as the WHO and IFPMA met in February 2026 to discuss global health architecture reforms, prioritizing environments that foster sustainable medical innovation.
See more
about 1D ago

ABBV stock price forecast

According to technical indicators for ABBV stock, the price is likely to fluctuate within the range of 224.71–253.69 USD over the next week. Market analysts predict that the price of ABBV stock will likely fluctuate within the range of 221.13–334.03 USD over the next months.

Based on 1-year price forecasts from 64 analysts, the highest estimate is 391.21 USD, while the lowest estimate is 254.52 USD.

For more information, please see the ABBV stock price forecast Stock Price Forecast page.

Latest ABBV stock news

US Stock Movement | Revolution Medicines Surges Over 13% in After-Hours Trading Amid Reports of Acquisition Talks with Merck for Up to $32 Billion

格隆汇2026-01-09 01:23:26

December Employment Data Falls Short of Projections as Jobless Rate Surprises Analysts

101 finance2026-01-09 14:33:42

Healthcare dealmakers head to San Francisco hoping for megamergers in 2026

101 finance2026-01-09 16:30:23

Abbvie, US reach agreement to cut drug prices

101 finance2026-01-13 00:03:28

AbbVie secures agreement with the Trump administration on medication pricing in return for tariff reductions

101 finance2026-01-13 09:24:29

Factbox-Global drugmakers rush to boost US presence as tariff threat looms

101 finance2026-01-13 13:21:24

AbbVie Plans to Expand in the Obesity Treatment Market

格隆汇2026-01-15 02:36:29

Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade

101 finance2026-01-15 12:24:24

Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows

101 finance2026-01-28 11:18:33

What’s Ahead in the Markets This Week: January Employment Data; Earnings Releases from Alphabet, Amazon, AMD, Disney, and Palantir

101 finance2026-02-01 11:06:48

January employment report, Alphabet and Amazon financial results, further impact from Warsh: Key events to follow this week

101 finance2026-02-01 12:51:28

AbbVie (ABBV) Q4 Results: Anticipated Outcomes

101 finance2026-02-03 03:30:37

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

101 finance2026-02-04 13:03:35

AbbVie: Q4 Financial Highlights

101 finance2026-02-04 13:15:10

3 Top-Performing Stocks Worth Investigating Further

101 finance2026-02-09 08:54:26

With just a Bitget account, you can trade stocks and cryptocurrencies at the same time.

Join now!

FAQ

What is the stock price of AbbVie Inc.?

ABBV is currently priced at 221.62 USD — its price has changed by -0.81% over the past 24 hours. You can track the stock price performance of AbbVie Inc. more closely on the price chart at the top of this page.

What is the stock ticker of AbbVie Inc.?

Depending on the exchange, the stock ticker may vary. For instance, on NYSE, AbbVie Inc. is traded under the ticker ABBV.

What is the stock forecast of ABBV?

We've gathered analysts' opinions on AbbVie Inc.'s future price. According to their forecasts, ABBV has a maximum estimate of 2216.15 USD and a minimum estimate of 443.23 USD.

What is the market cap of AbbVie Inc.?

AbbVie Inc. has a market capitalization of 391.68B USD.

What is P/E ratio (TTM)?

The P/E ratio (TTM) stands for price-to-earnings ratio (trailing twelve months). It is a historical valuation metric calculated using a company's earnings per share (EPS) over the most recent twelve consecutive months, reflecting the company's past profitability.

The P/E ratio measures the relationship between a stock's price and a company's profitability, and is often used as a basis for judging whether a stock is "cheap" or "expensive."

P/E ratio = market price (P) ÷ earnings per share (EPS), or P/E ratio = total market capitalization ÷ net profit attributable to shareholders

The interpretation of the P/E ratio (TTM) should always be considered alongside other factors and is mainly used for valuation comparisons rather than as a standalone indicator.

  • A lower P/E ratio (TTM) means investors are paying less for each unit of earnings. This may indicate that the stock is undervalued, or that the market has limited expectations for the company's future growth, such as in mature or slow-growing industries.
  • A higher P/E ratio (TTM) means investors are paying more for each unit of earnings. This often reflects expectations of strong future earnings growth, which is common among growth or technology stocks, though it may also suggest the stock is overvalued.
  • Comparison with peers: Compare the company's P/E (TTM) with the average or median P/E of other companies in the same industry. A significantly higher P/E may require further analysis to determine whether the company's high valuation is justified by stronger growth prospects or competitive advantages.
  • Comparison with historical levels: Compare the company's current P/E (TTM) with its own historical average (such as over the past 5 or 10 years) to assess whether the current valuation is at a historical high or low.
  • Comparison with the broader market: Compare the company's P/E (TTM) with major market indices (such as the S&P 500) to see how the market is valuing the company overall.

P/E ratios can vary widely across industries, and there is no single "ideal" P/E level. A reasonable P/E range depends on the industry, the company's growth potential, and the broader macroeconomic environment. Investment decisions should not rely solely on the P/E ratio (TTM) but should be based on a comprehensive analysis that includes company quality, growth prospects, and financial health.

Can I trade stocks on Bitget?

You can trade stocks on Bitget, but mainly through stock tokens and stock perps, rather than by directly buying or selling traditional stocks.

This approach reflects Bitget's vision as a Universal Exchange (UEX), designed to connect traditional financial markets with cryptocurrency markets.

Bitget currently offers the following stock-related trading formats:

1. Stock tokens (spot)

Nature: Stock tokens are digital tokens pegged to the price of specific traditional stocks (such as TSLAUSDT and NVDAUSDT) and are traded on Bitget's spot market.

Features: When you trade stock tokens, you are buying and holding tokens rather than owning the underlying traditional stocks.

  • The price of these tokens generally follows the price movements of the stocks they are pegged to, such as Tesla or Nvidia.
  • The advantage is that you can participate in the price movements of traditional financial assets, such as U.S. stocks, using cryptocurrencies (for example, USDT), without the need for a traditional brokerage account.

2. Stock perps

Nature: Bitget also offers USDT-margined perpetual futures, commonly referred to as stock perps, based on major U.S. blue-chip stocks such as Tesla and Meta.

Characteristics: Stock perps are derivative products that allow you to take a bullish or bearish view on the future price of an underlying stock through margin trading. These products typically support leverage, such as up to 25x.

It does not involve owning the underlying stock. Instead, profits and losses are settled based on price movements of the futures.

Important note: When trading stock perps on Bitget, you are participating in derivative markets within the cryptocurrency ecosystem. This is fundamentally different from purchasing publicly traded shares through a traditional brokerage, as you do not own equity in the underlying company.

Futures trading and the use of leverage involve high risk. Please ensure you fully understand the risks before trading.

If you wish to directly hold equity in traditional stocks and enjoy shareholder rights (such as receiving dividends), you must trade through a regulated traditional securities brokerage or brokerage platform.

What are the advantages of Bitget's stock perps?

Bitget's stock perps—typically perpetual futures based on stock tokens prices—are an innovative offering that allows cryptocurrency platforms to provide exposure to traditional financial markets.

Compared to traditional stock or futures trading, they offer several unique advantages, primarily due to the platform's trading infrastructure.

Bitget's stock perps, typically USDT-denominated derivatives, offer the following key advantages:

1. Trading convenience and global accessibility

  • 24/7 trading: Traditional stock markets, such as U.S. equity markets, operate during fixed trading hours. In contrast, cryptocurrency derivatives markets are typically open 24/7. This means investors can trade anytime, capitalizing on breaking news or market fluctuations.
  • Lower entry barriers and faster onboarding: Compared with traditional brokerages, which often require extensive identity verification and lengthy account setup processes, Bitget generally offers faster account onboarding. Users can trade using cryptocurrencies such as USDT, without the need for complex fiat deposit and withdrawal procedures.
  • Global accessibility: Users can access derivatives trading linked to globally recognized stocks via the Bitget platform, subject to applicable regulations.

2. Capital efficiency and high leverage

  • High leverage options: Stock perps typically offer higher leverage than traditional stock trading (for example, up to 25x). This allows traders to control larger positions with smaller margin requirements, improving capital efficiency.
    Note: While high leverage can amplify gains, it also amplifies losses proportionally.
  • Two-way trading: Traders can easily take both long and short positions. This means traders can potentially profit from market volatility whether stock prices rise or fall, provided the market direction is correctly anticipated.

3. Trading and settlement using cryptocurrency

  • USDT margin: Stock perps on Bitget typically use USDT (or other stablecoins) as the margin and settlement currency. For users who already hold cryptocurrency, there is no need to convert assets into fiat currency, allowing them to trade directly with stablecoins.
  • Efficient fund transfers: Crypto-based transfers and settlements are typically faster than traditional fiat systems, enabling more efficient global fund allocation.

4. Integration

One-stop platform: Bitget allows users to trade spot cryptocurrencies, crypto derivatives, and stock perps on a single platform, making it easier to manage different asset types in one place.

Risk warning:

While Bitget's stock perps offer several advantages, it is important to understand the associated risks.

  • High leverage risk: Leveraged trading can result in rapid loss of your entire margin.
  • No equity ownership: When trading stock perps, you do not own the underlying shares. As a result, you are not entitled to dividends or voting rights.
  • Market liquidity risk: Tokenized stock perps may have lower liquidity than their counterparts in traditional stock markets, especially outside regular trading hours.

In summary, Bitget's stock perps offer advantages such as greater trading flexibility, lower entry barriers, and higher capital efficiency.

What are the trading fees for Bitget stock perps?

Trading fees for Bitget stock perps (USDT-margined perpetual futures) mainly include transaction fees and funding rates.

Transaction fees:

Bitget offers limited-time fee promotions for stock perps (especially tokenized stock perps) from time to time to attract traders.

Standard reference rates: Under Bitget's standard futures fee structure, the taker fee is typically around 0.06%, while the maker fee is around 0.02%.

Current promotions for stock perps (important): To promote its stock perps products, Bitget is offering discounted transaction fees during Q4 2025, with taker fees as low as 0.006% and maker fees as low as 0.002%. There is also a limited-time promotion offering zero-fee trading for spot stock tokens.

Recommendation: Since promotional activities are subject to change or end at any time, please visit Bitget's official Fee overview or Announcement Center page for the latest and most accurate rates at the time of trading.

Funding rate:

The funding rate is a key mechanism in perpetual futures (including stock perps) that helps keep the futures price closely aligned with the spot price of the underlying asset. It is not a fee charged by the platform, but a periodic payment exchanged between long and short traders.

Funding rates fluctuate dynamically and are mainly driven by market sentiment and imbalances between long and short positions. Stock perps generally experience lower volatility than cryptocurrencies, so funding rates are often relatively low during stable market conditions. However, during earnings seasons or major positive or negative news events, heavy concentration of long or short positions—such as in high-growth technology stocks like Tesla or Nvidia—can create significant imbalances, causing funding rates to spike in the short term.

Funding payments are typically settled every 8 hours. If you close your position before the funding settlement time, no funding payment will be charged or received.

Funding rates are not fixed. If you hold a position for an extended period, high positive funding rates (for long positions) or high negative funding rates (for short positions) will affect your overall holding costs or potential returns. For this reason, it is important to monitor the funding rate in real time on the trading interface.

NYSE/
ABBV